Amgen Study Shows Repatha Cuts Heart Risks in High-Risk Diabetes Patients

New research from Amgen highlights the importance of early, intensive cholesterol management in patients with high-risk diabetes. A study showed that Repatha significantly lowered LDL cholesterol and reduced the risk of major cardiovascular events. The findings also compared outcomes for patients using other diabetes treatments, such as GLP-1 receptor agonists and SGLT2 inhibitors. People with diabetes are twice as likely to suffer a heart attack or stroke compared to those without the condition. The study focused on high-risk diabetes patients, where cardiometabolic issues like elevated LDL cholesterol often worsen outcomes.

Repatha demonstrated strong results in this group. Patients treated with the drug achieved a median LDL cholesterol level of 45 mg/dL, compared to 106 mg/dL for those on placebo. This reduction led to a 29% lower risk of coronary heart disease death, myocardial infarction, or ischemic stroke. The drug also cut the risk of a second composite endpoint—including ischemia-driven revascularization—by 21%. During the study, around one-third of participants were using SGLT2 inhibitors, while about one-fifth were on GLP-1 receptor agonists at some point. The benefits of Repatha remained consistent regardless of whether patients received these additional treatments. Amgen also presented real-world data showing that while GLP-1 therapies improve blood sugar control and weight, their effectiveness depends on continued use.

The findings suggest that early and aggressive LDL cholesterol reduction with Repatha can help prevent serious cardiovascular events in high-risk diabetes patients. The study reinforces the need for targeted cholesterol management alongside existing diabetes treatments. This approach may reduce long-term risks for a population already facing heightened cardiovascular dangers.